BenevolentAI Atopic Dermatitis Drug Fails To Deliver
Trk Inhibitor Does Not Significantly Reduce Itch and Inflammation
The UK artificial intelligence drug development expert has reported disappointing findings from a Phase II trial of lead candidate BEN-2293 in atopic dermatitis.
You may also be interested in...
BenevolentAI Goes Public In Europe’s Largest SPAC
The UK computational medicines specialist is listing on the Euronext Amsterdam after linking up with healthcare-focused special purpose acquisition corporation Odyssey which is advised by former Sanofi CEO Olivier Brandicourt.
Partner Or Go It Alone? TG Therapeutics Ponders EU Plans For Briumvi
TG Therapeutics has successfully launched Briumvi on its own in the US, despite fierce competition from established same-class MS drugs Ocrevus and Kesimpta, but is still weighing up the pros and cons of partnering for the European market.
Cosentyx Becomes First Biologic Approved For HS In Nearly A Decade
The Swiss major should have a considerable first-to-market advantage over other IL-17 biologics from the likes of UCB and Acelyrin that are also targeting the hidradenitis suppurativa space.